BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37185332)

  • 1. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
    Chauhan J; Grandits M; Palhares LCGF; Mele S; Nakamura M; López-Abente J; Crescioli S; Laddach R; Romero-Clavijo P; Cheung A; Stavraka C; Chenoweth AM; Sow HS; Chiaruttini G; Gilbert AE; Dodev T; Koers A; Pellizzari G; Ilieva KM; Man F; Ali N; Hobbs C; Lombardi S; Lionarons DA; Gould HJ; Beavil AJ; Geh JLC; MacKenzie Ross AD; Healy C; Calonje E; Downward J; Nestle FO; Tsoka S; Josephs DH; Blower PJ; Karagiannis P; Lacy KE; Spicer J; Karagiannis SN; Bax HJ
    Nat Commun; 2023 Apr; 14(1):2192. PubMed ID: 37185332
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Man F; Koers A; Karagiannis P; Josephs DH; Bax HJ; Gilbert AE; Dodev TS; Mele S; Chiarruttini G; Crescioli S; Chauhan J; Blower JE; Cooper MS; Spicer J; Karagiannis SN; Blower PJ
    Oncoimmunology; 2021; 10(1):1966970. PubMed ID: 34513315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
    Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Williams IP; Crescioli S; Sow HS; Bax HJ; Hobbs C; Ilieva KM; French E; Pellizzari G; Cox V; Josephs DH; Spicer JF; Karagiannis SN; Mele S
    MAbs; 2020; 12(1):1685349. PubMed ID: 31769737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
    Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
    Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
    Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
    Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.
    Wang Y; Sabbatino F; Wang X; Ferrone S
    Methods Mol Biol; 2014; 1102():523-35. PubMed ID: 24258997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
    Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
    Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
    Uranowska K; Samadaei M; Kalic T; Pinter M; Breiteneder H; Hafner C
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34318902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
    Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
    Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
    Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSPG4 in cancer: multiple roles.
    Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
    Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
    Javaid S; Terai K; Dudek AZ
    Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.
    Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
    Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
    Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
    Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.